- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dr Reddy's Labs launches generic Ocaliva in India
Dr Reddy's FXR™ is available in strengths of 5mg and 10mg tablets
Hyderabad: Dr Reddy's Laboratories has announced the launch of FXR™, a therapeutic equivalent generic version of Ocaliva® (obeticholic acid) in India, indicated for the treatment of Primary Biliary Cholangitis (PBC), in combination with Ursodeoxycholic Acid (UDCA) or as monotherapy in adults.
Commenting on the launch, M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr Reddy's Laboratories said, "We are excited to be the first generic company to market Obeticholic Acid in India. The launch of FXR™, the first-in-class Farnesoid X receptor agonist represents Dr Reddy's expertise to accelerate access to affordable alternatives for complex products. FXR™ will be an important addition to our Hepatology portfolio."
Dr Reddy's FXR™ is available in strengths of 5mg and 10mg tablets.
PBC is a rare chronic autoimmune disease, characterised by destruction of small bile ducts in the liver. The only approved treatment for PBC in India as of today is UDCA, which was approved almost two decades ago.
Though considered as a first-line treatment for PBC, up to 40% of the patients do not respond to UDCA treatment, leaving many PBC patients with no approved treatment option. In 2016, Obeticholic acid received accelerated approval for the treatment of PBC as an 'orphan drug' in the U.S.
Dr Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
The Company's markets include – USA, India, Russia & CIS countries, and Europe.
Read also: Dr Reddy's Labs gets USFDA EIR for Srikakulam formulations plant
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751